Evaxion to unveil three-year EVX-01 melanoma data at ESMO 2026
The Danish biotech will present phase 2 follow-up data on its personalized cancer vaccine, including results from a stand-alone treatment year, in Madrid this October.
Evaxion A/S announced on July 17, 2026 that it will present three-year clinical efficacy data from its phase 2 trial of personalized cancer vaccine candidate EVX-01 at the European Society for Medical Oncology Congress, to be held in Madrid, Spain, from October 23-27, 20261.
The new data set comes from a one-year extension of the phase 2 trial in patients with advanced melanoma, during which patients received EVX-01 as stand-alone therapy rather than in combination with anti-PD-1 treatment1.
The trial's earlier two-year results, already reported, showed an Objective Response Rate of 75%, with 12 of 16 patients achieving objective clinical responses and four reaching complete response1. A durable clinical benefit was observed, with 92% of patients still responding at the two-year follow-up and no relapses recorded1. Additionally, 54% of patients had a deepened response during treatment, and tumor reduction in target lesions was seen in 15 of the 16 enrolled patients1. EVX-01 induced an immune response in all patients, with 86% of targeted neoantigens generating specific T-cell responses1.
During the first two years, patients received EVX-01 alongside Merck's pembrolizumab, marketed as KEYTRUDA1, before a subset switched to EVX-01 alone in year three1.
The three-year findings will be presented as poster #2006P on October 24, 2026, from 12:00 to 12:45 CET1, by Dr. Muhammad Adnan Khattak of One Clinical Research, Hollywood Private Hospital and Edith Cowan University in Perth, Australia1. EVX-01 is Evaxion's lead clinical asset1.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.